Login / Signup

Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites.

Jianli TaoQi WangCarlos Mendez-DorantesKathleen H BurnsRoberto Chiarle
Published in: Nature communications (2022)
CRISPR/Cas9-based genome editing has revolutionized experimental molecular biology and entered the clinical world for targeted gene therapy. Identifying DNA modifications occurring at CRISPR/Cas9 target sites is critical to determine efficiency and safety of editing tools. Here we show that insertions of LINE-1 (L1) retrotransposons can occur frequently at CRISPR/Cas9 editing sites. Together with PolyA-seq and an improved amplicon sequencing, we characterize more than 2500 de novo L1 insertions at multiple CRISPR/Cas9 editing sites in HEK293T, HeLa and U2OS cells. These L1 retrotransposition events exploit CRISPR/Cas9-induced DSB formation and require L1 RT activity. Importantly, de novo L1 insertions are rare during genome editing by prime editors (PE), cytidine or adenine base editors (CBE or ABE), consistent with their reduced DSB formation. These data demonstrate that insertions of retrotransposons might be a potential outcome of CRISPR/Cas9 genome editing and provide further evidence on the safety of different CRISPR-based editing tools.
Keyphrases
  • crispr cas
  • genome editing
  • gene therapy
  • single cell
  • induced apoptosis
  • single molecule
  • drug delivery
  • genome wide
  • signaling pathway
  • cell proliferation
  • cancer therapy
  • endoplasmic reticulum stress